Clinical Trials
6 trialsNCT03820817 2026-05-26
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
Phase 1 Completed
NCT04249622 2025-09-16
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT06783153 2025-01-20
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
Phase 1/2 Not yet recruiting
NCT01345175 2024-05-14
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT05502913 2023-10-02
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
Soroka University Medical Center
Phase 2 Recruiting
NCT00967096 2013-11-27
Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)
Emory University
Phase 1 Completed